Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Free Cash Flow (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Free Cash Flow for 10 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 7.1% to -$3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$21.0 million, a 24.82% increase, with the full-year FY2024 number at -$22.3 million, down 12.54% from a year prior.
  • Free Cash Flow was -$3.5 million for Q3 2025 at Rein Therapeutics, up from -$6.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.6 million in Q3 2023 to a low of -$10.4 million in Q4 2023.
  • A 5-year average of -$5.6 million and a median of -$5.7 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 76.47% in 2023, then tumbled 169.22% in 2024.
  • Rein Therapeutics' Free Cash Flow stood at -$6.3 million in 2021, then rose by 29.51% to -$4.4 million in 2022, then plummeted by 135.68% to -$10.4 million in 2023, then soared by 53.69% to -$4.8 million in 2024, then rose by 26.27% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Free Cash Flow are -$3.5 million (Q3 2025), -$6.4 million (Q2 2025), and -$6.2 million (Q1 2025).